Literature DB >> 1527724

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

D R Sohn1, K Kobayashi, K Chiba, K H Lee, S G Shin, T Ishizaki.   

Abstract

To explore the relationship between omeprazole disposition and genetically determined S-mephenytoin 4'-hydroxylation phenotype status, we examined the kinetic variables of omeprazole and its two primary metabolites in plasma (5-hydroxyomeprazole and omeprazole sulfone) and the excretion profile of its principal metabolite in urine (5-hydroxyomeprazole) in eight extensive (EMs) and eight poor metabolizers (PMs) recruited from a Korean population. Each subject received a p.o. dose of 20 mg of omeprazole as an enteric-coated formulation, and blood and urine samples were collected up to 24 hr postdose. Omeprazole and its metabolites were measured by high-performance liquid chromatography with ultraviolet detection. The mean omeprazole area under the concentration-time curve (AUC), elimination half-life (T1/2) and apparent p.o. clearance were significantly (P less than .001) greater, longer and lower, respectively, in PMs than in EMs. The mean peak concentration and AUC of 5-hydroxyomeprazole and AUC ratio of 5-hydroxyomeprazole to omeprazole were significantly (P less than .01 to .001) less in PMs than in EMs. The mean peak plasma concentration, AUC of omeprazole sulfone and ratio of omeprazole sulfone to omeprazole were greater (P less than .001) and T1/2 was longer (P less than .001) in PMs than in EMs. The mean cumulative urinary excretion of 5-hydroxyomeprazole up to 24 hr postdose was significantly (P less than .001) less in PMs than in EMs. In addition, the log10 4'-hydroxymephenytoin excreted in urine correlated significantly (P less than .01) with the apparent p.o. clearance of omeprazole and half-lives of omeprazole, 5-hydroxyomeprazole and omeprazole sulfone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527724

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

2.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

3.  Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.

Authors:  Tsukasa Uno; Takenori Niioka; Makoto Hayakari; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2007-01-04       Impact factor: 2.953

Review 4.  Implications of pharmacogenetics for individualizing drug treatment and for study design.

Authors:  Christian Meisel; Thomas Gerloff; Julia Kirchheiner; Przemyslaw M Mrozikiewicz; Przemyslaw Niewinski; Jürgen Brockmöller; Ivar Roots
Journal:  J Mol Med (Berl)       Date:  2003-03-15       Impact factor: 4.599

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Authors:  T Sakai; N Aoyama; T Kita; T Sakaeda; K Nishiguchi; Y Nishitora; T Hohda; D Sirasaka; T Tamura; Y Tanigawara; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.

Authors:  Ahmad Settin; Ahmad Fathy Abdalla; Ayman S Al-Hussaini; Rizk El-Baz; Amr Galal
Journal:  Indian J Gastroenterol       Date:  2014-03-08

8.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

Authors:  K Chiba; A Saitoh; E Koyama; M Tani; M Hayashi; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

10.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.